{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:13:19Z","timestamp":1793884399574,"version":"4.7.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.eururo.2026.01.013","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T20:53:18Z","timestamp":1768855998000},"page":"302-304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Regional Node\u2013positive Bladder Cancer: Therapeutic Decisions Based on Trial Results in Perioperative and Advanced Disease Settings"],"prefix":"10.1016","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5286-9048","authenticated-orcid":false,"given":"Renate","family":"Pichler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Daniel","family":"Subiela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Scilipoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rehder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Grivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2026.01.013_b0005","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines","volume":"87","author":"van der Heijden","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.01.013_b0010","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.juro.2015.07.085","article-title":"A multi-institutional analysis of outcomes of patients with clinically node positive urothelial bladder cancer treated with induction chemotherapy and radical cystectomy","volume":"195","author":"Zargar-Shoshtari","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.01.013_b0015","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/bju.16319","article-title":"The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancer","volume":"134","author":"von Deimling","year":"2024","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.01.013_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2025.102377","article-title":"Prognostic implications of patients with clinically node positive bladder cancer undergoing radical cystectomy","volume":"23","author":"Scilipoti","year":"2025","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2026.01.013_b0025","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.euf.2017.05.006","article-title":"Lack of effectiveness of postchemotherapy lymphadenectomy in bladder cancer patients with clinical evidence of metastatic pelvic or retroperitoneal lymph nodes only: a propensity score-based analysis","volume":"5","author":"Necchi","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2026.01.013_b0030","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.eururo.2026.01.013_b0035","first-page":"S1763","article-title":"LBA2\u2003Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: the phase 3 KEYNOTE-905 study","volume":"36","author":"Vulsteke","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.01.013_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105544","article-title":"Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma","volume":"10","author":"van der Heijden","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.eururo.2026.01.013_b0045","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.01.013_b0050","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.eururo.2025.04.019","article-title":"Characterization of patients with lymph node only metastatic urothelial carcinoma treated with nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone from the CheckMate 901 trial","volume":"88","author":"Galsky","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.01.013_b0055","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.eururo.2025.05.015","article-title":"Consolidative surgery for advanced urothelial carcinoma following induction enfortumab vedotin and\/or immune checkpoint inhibitor therapy: a multicenter analysis","volume":"88","author":"Roberson","year":"2025","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826000199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826000199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:23:24Z","timestamp":1773872604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283826000199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0302283826000199"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2026.01.013","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regional Node\u2013positive Bladder Cancer: Therapeutic Decisions Based on Trial Results in Perioperative and Advanced Disease Settings","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2026.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}